Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib vs Chemoradiotherapy in Unresectable Stage III ALK+ Lung Adenocarcinoma
NCT06858410Phase 3Not yet recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of lorlatinib in lung adenocarcinoma (2 arms), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Progression Free Survival at 36 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06858410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858410.